Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTRUSION: Tusamitamab ravtansine PK/PD study
NCT05703555Phase 2Withdrawn
- Sponsor
- Erasmus MC
- Start
- Feb 2024
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tusamitamab ravtansine in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), breast cancer, gastric cancer (GC), sponsored by Erasmus MC. Planned start Feb 2024; status: withdrawn.
02
Drugs
tusamitamab ravtansine
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT05703555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703555.